IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency
Background: Patients suffering from heart failure (HF) and iron deficiency (ID) have worse outcomes. Treatment with intra-venous (IV) ferric carboxymaltose has been shown to reduce HF rehospitalizations and to improve functional capacity and symptoms in patients with HF and reduced ejection fraction...
Main Authors: | Itay Borreda MD, Robert Zukermann MD, Danny Epstein MD, Erez Marcusohn MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-01-01
|
Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
Online Access: | https://doi.org/10.1177/10742484211055639 |
Similar Items
-
Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors
by: Erez Marcusohn, et al.
Published: (2021-11-01) -
Ferric Carboxymaltose in Patients with Acute Decompensated Heart Failure and Iron Deficiency: A Real-Life Study
by: Federico Capone, et al.
Published: (2023-08-01) -
The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis
by: Antonio Lacquaniti, et al.
Published: (2023-06-01) -
IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia
by: Sree Chandana Damineni, et al.
Published: (2016-11-01) -
Comparison of Ferric Sodium EDTA in Combination with Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate, and Selenomethionine as Therapeutic Option for Chronic Kidney Disease Patients with Improvement in Inflammatory Status
by: Antonella Giliberti, et al.
Published: (2022-05-01)